RxDoctor Payments Data

Wirt Hines, MD

MOHS-Micrographic Surgery · Anacortes, WANPI 1194762898

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.9% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 40.9% of the total. Reporting peaked in 2024 at $1,316 and has fallen 60.5% since, to $520 in 2025.

$3,398in general payments, 2019–2025

Across 100 payments — averaging $33.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sun Pharmaceutical Industries Inc.$522
  • UCB, Inc.$378
  • Regeneron Healthcare Solutions, Inc.$165
  • Organogenesis Inc.$163
  • Sanofi$143
  • plus $637 from 14 others

What the payments were for

  • Food & beverage$3,22695%
  • Education$1725%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,398 in reported general payments places this provider in the 65th percentile of 38 mohs-micrographic surgery providers in Washington.

See all mohs-micrographic surgery providers in Washington

Medicare billing

Part B allowed, 2024
$922,197
Medicare patients
1,232
Services billed
8,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab25$93,989
Fluorouracil76$5,354
Ketoconazole183$3,978
Betamethasone Dipropionate61$3,386
Clobetasol Propionate53$2,286
Metronidazole58$2,073
Triamcinolone Acetonide106$1,687
Betamethasone Valerate65$1,396
Doxycycline Hyclate55$1,006
Imiquimod22$551
Clindamycin Phosphate12$419
ValacyclovirValacyclovir Hcl12$280
Hydrocortisone34$152
MethotrexateMethotrexate Sodium15$142
Cephalexin29$140

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Anacortes

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →